Question 1: Applying Research Concepts to Nes et al., 2024 EPIO Trial Research Design The EPIO study adopted a parallel

Question 1: Applying Research Concepts to Nes et al., 2024 EPIO Trial

Research Design

The EPIO study adopted a parallel group randomized controlled trial (RCT) design, with a digital self-management intervention group against a usual care group.13 Typically, this design is the best to test causality since it is the best and does not consolidate on any confounding causes. The 12-month follow up enhances inference to conclude on the effects being sustained as opposed to being changed just in the short term, and this is especially crucial with chronic pain interventions in which the implications of being able to sustain improvements is of clinical importance.

Sample Size

The study involved 266 participants (1:1 control of EPIO versus usual care), which gave it moderate statistical power to detect clinically significant differences based on psychological and quality-of-life outcomes (Nes et al., 2024). Sample size planning is the technique of design to balance desired power (usually 80 cent), variability in the result, period and effect size anticipated to be observed, and the anticipated dropout rate. This sample is plausible but prone to the loss of power in cases of a high attrition rate than predicted in case of a small-to-moderate effect size on psychosocial outcomes. In order to retain power, the authors reported the baseline and 12-month numbers.

Validity

Internal validity that is also referred to as attribution or modifiable effects identifies the effect of an intervention observed due to a bias or confounding. Randomization and pre-specified outcomes in EPIO trial was used to enhance the internal validity, but participant blinding was not possible in a digital self-management program (Nes et al., 2024). This non-blindness may result in performance and detection bias, which the researchers took care of through validated questionnaires and when practiced through blinded assessments.

External validity has to do with generalization. Participants recruited by EPIO had to be in a position to interact with digital programs, discarding them as not applicable to individuals with no internet, low digital literacy, as well as with different health systems. Findings are relevant to connect digitally related adults experiencing chronic pain in other healthcare settings.

Subject Selection

The inclusion criterion applied on the selection of the subject included chronic pain and digital capability, which create a suitable study population but result in the selection of subjects according to the access to digital resources and motivation. The​‍​‌‍​‍‌​‍​‌‍​‍‌ effect of confounders, both those that were measured and those that were unmeasured, has been equalized to a large extent, and this is why we decided to distribute participants among groups in such a way that bias would be prevented by the application of objective standardized instruments and blinded assessors if necessary. Bias due to participation could not be prevented: in order to tackle the problem, we decided to assign participants to groups so that bias could be prevented as much as possible by the use of objective standardized instruments and blinded assessors where needed.

Ethical Considerations

The EPIO trial instruments involved the use of informed consent, the approval of ethics, and the surveillance of adverse events. Of course, digital ethics deals with the privacy of the information, the safe use of health data, and access to the clinical support if the participants need it. The question of providing access to all can become a problem because digital trials can disenfranchise people who have a poor level of digital literacy or bad internet ​‍​‌‍​‍‌​‍​‌‍​‍‌connection.

Generalizability

The results that EPIO enhanced anxiety, depression, self-regulatory fatigue, and quality of life attest to its usefulness in digitally connected adults with chronic pain, although the results cannot be extrapolated to the wider population that aligns with the inclusion criteria and has access to eHealth and ease. There may be variations in culturally, linguistically, socioeconomically, and health-system different programs, and by doing the same in heterogeneous samples, program performance would be reinforced by external validity (Nes et al., 2024).

Question 2: Outside Article

Selected Article

Hashimoto, T., Putman, R., McGough, K., McCabe, K. K., et al. (2024). Study protocol for a randomized controlled trial: Integrating the 'Time-limited Trial' in the emergency department.

Discussion and Appraisal

The protocol covers a pragmatic RCT in the US emergency departments that will treat a time-limited intervention of trial among the seriously ill older adults (Hashimoto et al., 2024). The study demonstrates a high level of pre-planning in the ClinicalTrials.gov registration of the trial, pre-specified outcome, and robust publication of the software used in the trial that will decrease publication bias and switching of outcomes (Chan et al., 2025).

The pragmatic setting presents issues such as possible contamination across arms and non-adherence to intervention which the randomized design does not exclude and promotes internal validity. Participant and clinician effects can never be blinded from this behavioral intervention and therefore the protocol appropriately uses blinded outcome assessors if possible, to reduce detection bias (Hashimoto et al., 2024).

To support the external validity, incorporating the intervention into the routine of the ED would be more probable to be able to apply the results in other US emergency department, although they might not be applicable to other health systems and EDs that have different staffing arrangements. Emergency situations introduce special ethical concerns of consent capacity, and to which the protocol displays sensitive consent protocols and monitoring (Hashimoto et al., 2024).

In total, the trial balances approach will be able to balance the methodological rigor and the applicability into the real world and will provide a beneficial piece of evidence regarding the implementation of goals-of-care discussion into the workflow in the acute-care setting.

Question 3: Case-Control Study Characteristics.

Correct Answer

The only exception is statement 3: "Incidence rates can be calculated directly. This is not typical of case-control studies.”

Case-control studies choose subjects using disease status (cases vs. controls) and investigates previous exposures and summarize them, hence they do not track a population over a period of time to observe the occurrence of new cases. The absence of the need to follow a cohort at risk enables researchers to not calculate person-time or estimate true incidence rates. (Tenny et al., 2021).

Mathematical illustration:

Ø  Cohort study: Follow 1,000 exposed persons for 5 years = 5,000 person-years; observe 50 cases

Incidence rate = 50/5,000 = 10/1,000 person years.

Causal - methods: Interventional case-control study - select 200 cases and 200 controls 1, 2 Case-Control Study 1. Pick 200 cases and 200 controls; 150/200 cases were exposed vs. 50/200 controls Case-Control Study 2. Pick 200 cases and 200 controls; 150/200 cases were exposed vs. 50/200 controls Authentication of a study: It should be reproducible by others.

Ø  Can calculate odds ratio = (150/50)/(50/150) = 9.0

Ø  Cannot calculate incidence rate (lacks person-time denominator)

Case-control researchers calculate odds ratios that are approximations of relative risk under specific circumstances but not incidence rates (Labrecque and Swanson, 2021).

Why Other Statements HAVE it Right.

1. Inexpensive compared with most other epidemiologic study designs - Yes. Case-control studies have no follow-up, have smaller samples, and take less time than cohort studies, and are so effective in rare diseases (Tenny et al., 2023).

2. Patients compared to persons without the disease - Yes. it involves the selection based on disease status, and the exposure of the groups is compared (Tenny et al., 2023).

3. Incident rates may be computed directly – Yes. The statistics were taken directly from the field, but it is not documented directly whether the statistics were directly document during data population. Which may have affected the statistics carried out.

4. Biased Assessment of past exposure - Yes. One of the key weaknesses is recall bias, which can cause the cases to recall exposures in comparison to controls and permits retrospective assessment to misclassify (Tennye et al., 2023).

5. Definition of cases may be difficult - Yes. Syndromic conditions are difficult to set up with consistent definition of cases without gold-standard diagnostics, and poor definitions cause misclassification bias.

References

Chan, A. W., Tunn, R., Collins, G. S., et al. (2025). SPIRIT 2025 statement: Updated guideline for protocols of randomized trials. JAMA.

Hashimoto, T., Putman, R., McGough, K., McCabe, K. K., et al. (2024). Study protocol for a randomized controlled trial: Integrating the 'Time-limited Trial' in the emergency department. PLoS ONE.

Hopewell, S., Chan, A. W., Collins, G. S., et al. (2025). CONSORT 2025 statement: Updated guideline for reporting randomized trials. Nature Medicine.

Labrecque, J. A., & Swanson, S. A. (2021). Do case-control studies always estimate odds ratios? American Journal of Epidemiology, 190(2), 318–325.

Nes, L. S., Børøsund, E., Varsi, C., Eide, H., Waxenberg, L. B., Weiss, K. E., Morrison, E. J., Støle, H. S., Kristjansdottir, Ó. B., Bostrøm, K., Strand, E. B., Hagen, M. C. S., Stubhaug, A., & Schreurs, K. M. (2024). Living well with chronic pain: a 12-month randomized controlled trial revealing impact from the digital pain self-management program EPIO. PAIN Reports, 9(4), e1174.

Pérez-Guerrero, E. E., Camacho-Zamora, B. D., Escoto-Delgadillo, M., Camacho-Zamora, P., Osuna-Ramírez, I., & Garibaldi-Covarrubias, R. (2024). Case definition for vector-borne diseases: A narrative review. Pathogens, 13(2), 175.

Tenny, S., & Hoffman, M. (2023). Case control studies. In StatPearls. StatPearls Publishing.